– Reuters
Benchmark Maintains Buy on Bio-Techne, Maintains $120 Price Target
Benchmark analyst Robert Wasserman maintains Bio-Techne (NASDAQ:TECH) with a Buy and maintains $120 price target.
Related Posts
Cracker Barrel Old Country Store Reports Q2 Earnings Above Street View
Cracker Barrel Old Country Store Inc (NASDAQ:CBRL) reported second-quarter FY23 sales growth of 8.3% year-on-year to $933.87 million, beating the consensus…
Mizuho Maintains Buy on Credo Technology Group, Lowers Price Target to $16
Mizuho analyst Vijay Rakesh maintains Credo Technology Group (NASDAQ:CRDO) with a Buy and lowers the price target from $20 to $16.
Why PTC Therapeutics Shares Are Gaining Today
PTC Therapeutics Inc (NASDAQ: PTCT) says its APHENITY Phase 3 trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU) has